Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 8/20 | 0.38 |
| ▸ | ACACB | O00763 | 3/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.32 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15968677 | 0.93 | KMO (0.40) | KMOGRM2ACACBS1PR1MAP4K4 | |
| SCHEMBL15968096 | 0.90 | S1PR5 (0.38) | GRM2ACACBS1PR1 | |
| SCHEMBL15968161 | 0.88 | GRM2 (0.36) | KMOGRM2ACACBTRPV1 | |
| SCHEMBL15968929 | 0.88 | ACACB (0.49) | ACACB | |
| SCHEMBL15998327 | 0.87 | KMO (0.40) | KMOGRM2ACACBS1PR1 | |
| SCHEMBL15969123 | 0.82 | S1PR5 (0.40) | GRM2ACACBS1PR1 | |
| SCHEMBL15968836 | 0.82 | KMO (0.46) | KMOGRM2S1PR1CNR2CNR1 | |
| SCHEMBL15968237 | 0.81 | GRM2 (0.36) | KMOGRM2ACACBTRPV1 | |
| SCHEMBL15968530 | 0.81 | ACACB (0.49) | ACACB | |
| SCHEMBL15968492 | 0.80 | GRM2 (0.43) | KMOGRM2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | KMO 2615/4885GRM2 2148/4885ACACB 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.